Cargando…
Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients
The study was undertaken to evaluate macrophage-derived chemokine (CCL22) levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n = 93) in relation to regulatory T cells (Tregs; n = 75). The peritoneal fluid CCL22 concentrations were significantly higher in epithelial ovari...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529457/ https://www.ncbi.nlm.nih.gov/pubmed/25647263 http://dx.doi.org/10.1007/s13277-015-3133-8 |
_version_ | 1782384797114433536 |
---|---|
author | Wertel, I. Surówka, J. Polak, G. Barczyński, B. Bednarek, W. Jakubowicz-Gil, J. Bojarska-Junak, A. Kotarski, J. |
author_facet | Wertel, I. Surówka, J. Polak, G. Barczyński, B. Bednarek, W. Jakubowicz-Gil, J. Bojarska-Junak, A. Kotarski, J. |
author_sort | Wertel, I. |
collection | PubMed |
description | The study was undertaken to evaluate macrophage-derived chemokine (CCL22) levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n = 93) in relation to regulatory T cells (Tregs; n = 75). The peritoneal fluid CCL22 concentrations were significantly higher in epithelial ovarian cancer (EOC) patients than in patients with benign tumors-serous cystadenoma (n = 32). There was no difference in plasma levels of CCL22 in EOC patients compared with the non-cancer and healthy volunteers (n = 10). There were no significant differences in the plasma and PF CCL22 levels based on tumor grade. However, women with stage IV FIGO (International Federation of Gynecologists and Obstetricians) had significantly higher plasma CCL22 levels than patients with stages I and III. Women with stage I FIGO had significantly higher PF CCL22 levels than patients with stages II and III. Women with endometrioid cystadenocarcinoma had higher PF CCL22 levels than women with undifferentiated carcinoma. The percentage of tumor-infiltrating Tregs (11.06 %) was significantly higher compared to PF (3.05 %) and peripheral blood (PB) (2.01 %). Moreover, the percentage of Tregs was higher in the PF than in the PB of EOC patients. There were no significant differences in the PB, PF, and tumor-infiltrating Tregs percentage based on tumor stage, grade, or histology. Elevated levels of CCL22 found in the ascites could create a chemokine gradient aiding in Treg cells migration. Increased Tregs percentage in the local microenvironment of ovarian cancer might be an important mechanism of immunosuppression. |
format | Online Article Text |
id | pubmed-4529457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-45294572015-08-11 Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients Wertel, I. Surówka, J. Polak, G. Barczyński, B. Bednarek, W. Jakubowicz-Gil, J. Bojarska-Junak, A. Kotarski, J. Tumour Biol Research Article The study was undertaken to evaluate macrophage-derived chemokine (CCL22) levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n = 93) in relation to regulatory T cells (Tregs; n = 75). The peritoneal fluid CCL22 concentrations were significantly higher in epithelial ovarian cancer (EOC) patients than in patients with benign tumors-serous cystadenoma (n = 32). There was no difference in plasma levels of CCL22 in EOC patients compared with the non-cancer and healthy volunteers (n = 10). There were no significant differences in the plasma and PF CCL22 levels based on tumor grade. However, women with stage IV FIGO (International Federation of Gynecologists and Obstetricians) had significantly higher plasma CCL22 levels than patients with stages I and III. Women with stage I FIGO had significantly higher PF CCL22 levels than patients with stages II and III. Women with endometrioid cystadenocarcinoma had higher PF CCL22 levels than women with undifferentiated carcinoma. The percentage of tumor-infiltrating Tregs (11.06 %) was significantly higher compared to PF (3.05 %) and peripheral blood (PB) (2.01 %). Moreover, the percentage of Tregs was higher in the PF than in the PB of EOC patients. There were no significant differences in the PB, PF, and tumor-infiltrating Tregs percentage based on tumor stage, grade, or histology. Elevated levels of CCL22 found in the ascites could create a chemokine gradient aiding in Treg cells migration. Increased Tregs percentage in the local microenvironment of ovarian cancer might be an important mechanism of immunosuppression. Springer Netherlands 2015-02-03 /pmc/articles/PMC4529457/ /pubmed/25647263 http://dx.doi.org/10.1007/s13277-015-3133-8 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Research Article Wertel, I. Surówka, J. Polak, G. Barczyński, B. Bednarek, W. Jakubowicz-Gil, J. Bojarska-Junak, A. Kotarski, J. Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients |
title | Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients |
title_full | Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients |
title_fullStr | Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients |
title_full_unstemmed | Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients |
title_short | Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients |
title_sort | macrophage-derived chemokine ccl22 and regulatory t cells in ovarian cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529457/ https://www.ncbi.nlm.nih.gov/pubmed/25647263 http://dx.doi.org/10.1007/s13277-015-3133-8 |
work_keys_str_mv | AT werteli macrophagederivedchemokineccl22andregulatorytcellsinovariancancerpatients AT surowkaj macrophagederivedchemokineccl22andregulatorytcellsinovariancancerpatients AT polakg macrophagederivedchemokineccl22andregulatorytcellsinovariancancerpatients AT barczynskib macrophagederivedchemokineccl22andregulatorytcellsinovariancancerpatients AT bednarekw macrophagederivedchemokineccl22andregulatorytcellsinovariancancerpatients AT jakubowiczgilj macrophagederivedchemokineccl22andregulatorytcellsinovariancancerpatients AT bojarskajunaka macrophagederivedchemokineccl22andregulatorytcellsinovariancancerpatients AT kotarskij macrophagederivedchemokineccl22andregulatorytcellsinovariancancerpatients |